Your browser doesn't support javascript.
loading
Nitrothiazole-Thiazolidinone Hybrids: Synthesis and in Vitro Antimicrobial Evaluation.
Hart, Dylan; Legoabe, Lesetja J; Jesumoroti, Omobolanle J; Jordaan, Audrey; Warner, Digby F; Steventon, Rebecca; Beteck, Richard M.
Afiliação
  • Hart D; Center of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.
  • Legoabe LJ; Center of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.
  • Jesumoroti OJ; Center of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.
  • Jordaan A; SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Observatory, 7925, South Africa.
  • Warner DF; SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Department of Pathology, University of Cape Town, Observatory, 7925, South Africa.
  • Steventon R; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, 7701, South Africa.
  • Beteck RM; Welcome Center for Infectious Diseases Research in Africa (CIDRI-Africa), Faculty of Health Sciences, University of Cape Town, Rondebosch, 7701, South Africa.
Chem Biodivers ; 19(11): e202200729, 2022 Nov.
Article em En | MEDLINE | ID: mdl-36102043
ABSTRACT
Herein we report the synthesis of novel compounds inspired by the antimicrobial activities of nitroazole and thiazolidin-4-one based compounds reported in the literature. Target compounds were investigated in vitro for antitubercular, antibacterial, antifungal, and overt cell toxicity properties. All compounds exhibited potent antitubercular activity. Most compounds exhibited low micromolar activity against S. aureus and C. albicans with no overt cell toxicity against HEK-293 cells nor haemolysis against human red blood cells. Notably, compound 3b exhibited low to sub-micromolar activities against Mtb, MRSA, and C. albicans. 3b showed superior activity (0.25 µg/ml) against MRSA compared to vancomycin (1 µg/ml).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Staphylococcus aureus / Anti-Infecciosos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Staphylococcus aureus / Anti-Infecciosos Idioma: En Ano de publicação: 2022 Tipo de documento: Article